Most Read

Sanofi has completed the acquisition of messenger RNA (mRNA) therapies firm Translate Bio to expedite the use mRNA technology for the development of treatments and vaccines. The latest move

US-based biopharmaceutical firm AzurRx BioPharma has agreed to acquire clinical-stage biotechnology company First Wave Bio in a stock-and-cash deal valued at $229m. First Wave Bio is focussing on

The UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) has approved Amgen’s sotorasib (Lumakras) to treat patients with specific non-small cell lung cancer with KRAS G12C mutation. To be

EnGeneIC has started dosing in Phase I clinical trial of the world’s first nanocellular technology-based anti-Covid-19 vaccine in healthy adults. Referred to as EnGeneIC Dream Vector (EDV), the

The European Medicines Agency (EMA) has started evaluation of the data on a booster (third) dose for the Covid-19 vaccine, Comirnaty, developed by Pfizer and BioNTech. The move

Swedish Orphan Biovitrum (Sobi) has agreed a $8bn (SEK69.4bn) takeover offer from Advent International and Singapore’s wealth fund GIC. Sobi’s board of directors had unanimously recommended that shareholders

Merck and Ridgeback Biotherapeutics have initiated a Phase III clinical trial to evaluate investigational oral antiviral therapeutic molnupiravir to prevent Covid-19 infection. For the global MOVe-AHEAD study, individuals

Teva Pharmaceuticals and MedinCell’s new drug application (NDA) for their drug, TV-46000/mdc-IRM to treat schizophrenia has been accepted by the US Food and Drug Administration (FDA). Intended for

The US Food and Drug Administration (FDA) has approved an expanded indication for UCB’s Briviact (brivaracetam) CV as monotherapy or adjunctive therapy for the treatment of partial-onset seizures